Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review
Authors:
Open Access
- 2 September 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 22 (9) , 975-988
Abstract
1. Biologic therapies have been used successfully to treat many conditions, but are often associated with high costs due in part to the complexity of drug development [1,2]. After patent expiry and...Keywords
Funding Information
- Sandoz/Hexal AG
This publication has 91 references indexed in Scilit:
- Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative ReviewDermatology and Therapy, 2023
- Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisBioDrugs, 2023
- Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator EtanerceptBioDrugs, 2021
- Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory PerspectiveDrugs, 2021
- Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisJAMA Dermatology, 2021
- The Path Towards a Tailored Clinical Biosimilar DevelopmentBioDrugs, 2020
- The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic ReviewClinical Pharmacology & Therapeutics, 2020
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical OutcomesDrugs, 2018
- Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar InfliximabArthritis & Rheumatology, 2017
- The Diversity of Biosimilar Design and Development: Implications for Policies and StakeholdersBioDrugs, 2015